## Natco Pharma Limited (NATCOPHARM) Stock Analysis

This report analyzes Natco Pharma Limited's stock performance based on the provided data.  The analysis focuses on key financial metrics, shareholding patterns, corporate actions, and recent announcements to determine a buy, sell, or hold recommendation.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | NATCOPHARM                |
| Company Name     | Natco Pharma Limited      |
| Industry         | Pharmaceuticals           |
| Listing Date     | 1995-12-27                |
| ISIN             | INE987B01026              |


**1.2 Market Data:**

| Metric                | Value       |
|-----------------------|-------------|
| Last Price            | 1,425.15     |
| Change                | -51.65      |
| % Change              | -3.50%      |
| Previous Close        | 1,476.80    |
| Open                  | 1,480.50    |
| Close                 | 1,416.95    |
| VWAP                  | 1,444.28    |
| Week High             | 1,639.00    |
| Week Low              | 755.00      |
| Sector PE             | 13.61       |
| Symbol PE             | 13.61       |
| Total Traded Volume   | 480,121     |
| Delivery Quantity     | 217,777     |
| Delivery %            | 45.36%      |
| CM Daily Volatility   | 1.96        |
| CM Annual Volatility  | 37.45       |


**1.3 Pre-Open Market Data:**

The pre-open market showed a slight increase in price compared to the previous close, with the final pre-open price at 1480.5.  However, this is not a significant indicator on its own.

**1.4 Corporate Actions:**

| Ex-Date       | Purpose                               |
|---------------|---------------------------------------|
| 27-Nov-2024   | Interim Dividend - Rs 1.50 Per Share  |
| 23-Aug-2024   | Interim Dividend - Rs 3 Per Share     |
| 26-Feb-2024   | Interim Dividend - Rs 1.25 Per Share  |
| 24-Nov-2023   | Interim Dividend - Rs 1.25 Per Share  |
| 22-Aug-2023   | Interim Dividend - Rs 7 Per Share     |
| 21-Feb-2023   | Interim Dividend - Rs 1.25 Per Share  |


**1.5 Recent Announcements:** (Selection of most relevant)

* 09-Dec-2024: Updates
* 27-Nov-2024: Press Release
* 21-Nov-2024: Analysts/Institutional Investor Meet/Con. Call Updates


**1.6 Financial Results (Last Five Quarters):**

| Quarter      | Income     | Expenditure | Profit After Tax | Diluted EPS |
|--------------|------------|-------------|-----------------|-------------|
| Q3 FY2025    | 134,400    | 54,710      | 66,110          | 36.91       |
| Q2 FY2025    | 127,670    | 51,870      | 63,630          | 35.53       |
| Q1 FY2025    | 100,070    | 56,820      | 34,910          | 19.49       |
| Q4 FY2024    | 65,480     | 43,120      | 19,200          | 10.72       |
| Q3 FY2024    | 95,520     | 53,120      | 36,020          | 20.11       |


**1.7 Shareholding Patterns:**

| Date         | Promoter & Promoter Group | Public |
|--------------|--------------------------|--------|
| 30-Sep-2023  | 49.71%                     | 50.29% |
| 31-Dec-2023  | 49.71%                     | 50.29% |
| 31-Mar-2024  | 49.71%                     | 50.29% |
| 30-Jun-2024  | 49.71%                     | 50.29% |
| 30-Sep-2024  | 49.62%                     | 50.38% |

Promoter holdings have slightly decreased in the last quarter.


**1.8 Key Directors and Contact Information:**

(Data provided, but omitted for brevity.  Available upon request.)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

The current price shows a significant decrease (-3.50%) compared to the previous close.  However, it's important to note the recent week high and low, indicating considerable volatility.  The pre-open activity suggested a slight upward movement, but this was not sustained.

**2.2 Financial Performance:**

Revenue and profitability show some fluctuation over the last five quarters.  Diluted EPS also varies, indicating inconsistent earnings.  Further investigation into the reasons for these fluctuations is needed.

**2.3 Shareholding Analysis:**

Promoter holdings have shown a slight decrease, which could be a cause for concern, although the change is minimal.

**2.4 Corporate Action Summary:**

The company has consistently paid interim dividends over the past year, indicating a commitment to shareholder returns.

**2.5 Volatility and Risk:**

The daily and annual volatility metrics (1.96% and 37.45% respectively) suggest a relatively high-risk investment.

**3. Final Verdict:**

**Hold.**

While Natco Pharma has a history of paying dividends and shows some profitability, the recent price drop, coupled with high volatility and a slight decrease in promoter holdings, warrants a cautious approach.  The inconsistent financial performance over the last five quarters also raises concerns.  More detailed analysis of the recent announcements and the reasons behind the financial fluctuations is needed before considering a buy.  The current data does not provide sufficient confidence to recommend a buy.  A "hold" allows for further observation and analysis before making a more informed decision.

**Conclusion:**

Based solely on the provided data, Natco Pharma presents a mixed picture.  While dividend payments are positive, the volatility, recent price drop, and inconsistent financial performance outweigh the positive aspects.  Further investigation is crucial before making a definitive investment decision.
